Advanced Treatments and Emerging Therapies for Dystrophin- Deficient Cardiomyopathies

@inproceedings{Camps2017AdvancedTA,
  title={Advanced Treatments and Emerging Therapies for Dystrophin- Deficient Cardiomyopathies},
  author={Jordi Camps and Enrico Pozzo and Tristan Pulinckx and Robin Duelen and Maurilio Sampaolesi},
  year={2017}
}
Dystrophinopathies are characterized by skeletal and cardiac muscle complications because of a lack or shortened DYSTROPHIN protein. Ventilation assistance and corticosteroid treatment have positively affected life outcome but lead to an increased incidence of cardiomyopathy. Cardiomyopathy is now the leading cause of death in patients with dystrophinopathy. Thus, coherent guidelines for cardiac care have become essential and need to be communicated well. Progression of cardiac complications in… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 86 REFERENCES

Dystrophin-Deficient Cardiomyopathy.

  • Journal of the American College of Cardiology
  • 2016
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Treatment of dystrophin cardiomyopathies

  • Nature Reviews Cardiology
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Long-term ventilation of patients with Duchenne muscular dystrophy: experiences at the Neuromuscular Centre Ulm

  • Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Cardiac assessment in duchenne and becker muscular dystrophies.

  • Current heart failure reports
  • 2010
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…